α-synuclein pathology in aging and Alzheimer's: A CSF study

View profile for Andrés D. Klein

Creativity is as important as knowledge / Director, Ph.D. Program in Sciences and Innovation in Medicine at Universidad del Desarrollo

Effects of α-synuclein pathology in normal aging and Alzheimer’s disease A study using a cerebrospinal fluid (CSF) seed amplification assay (SAA) investigated the presence of pathological α-synuclein, a key biomarker for Lewy body disease (LBD), in clinically unimpaired (CU) individuals and those with Alzheimer's disease (AD). The results showed α-synuclein positivity in 9% of CU, 14% of mild cognitive impairment (MCI), and 19% of AD dementia participants, significantly lower than the 81% seen in a dedicated LBD cohort. Within the CU group, those who were α-synuclein positive were older and showed poorer performance in executive function and working memory, along with more self-reported LBD-related non-motor symptoms. Interestingly, α-synuclein status in CU participants wasn't linked to AD biomarkers (amyloid or tau), memory performance, or motor symptoms. The study, available as a Preprint https://lnkd.in/eSudBkPj concludes that the CSF SAA test for α-synuclein can independently predict subtle cognitive changes and early clinical symptoms in aging adults, adding to the understanding of α-synuclein's role in clinically healthy and AD-affected populations. #genetics #genomics #precisionmedicine #genomicmedicine #brain #neurology #neuroscience #neurodegeneration #neuroinflammation #inflammation #immunity #metabolism #aging #longevity #cognition #dementia #alzheimer #parkinson #raredisease #gerosciene #biomarkers #therapeutics #biotechnology #innovation #research #clinicalresearch #science #sciencecommunication

Thanks for the very interesting information or article.

Like
Reply
Rene Anand

Chief Executive Officer and Founder of Neurxstem Inc.

3w

👌

This study highlights promising advances in early detection of neurodegenerative changes. How might integrating CSF SAA testing impact personalized treatment strategies?

Like
Reply
Dr. Reza Rahavi

Experimental Medicine , Faculty of Medicine, UBC, Vancouver | Medical Content Writing

2w

This study adds valuable insight into α-synuclein's role in aging and cognitive decline. Do you see this biomarker influencing early interventions soon? Your words inspire connect today?

Like
Reply
Ken Wasserman

Assistant Professor at Georgetown University School of Medicine

3w

"Using the CSF [seed amplification assay] SAA biomarker, α-syn positivity independently predicts subtle cognitive changes and early clinical symptoms in aging. These cross-sectional findings represent an important addition to the limited but growing literature characterizing the frequency and effects of α-syn positivity in clinically healthy older adults and individuals with AD."

Like
Reply
See more comments

To view or add a comment, sign in

Explore content categories